RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > 2021 > 8 > Recon: FDA investigates iPhone-pacemaker interference; Humacyte's $245M SPAC deal

Recon: FDA investigates iPhone-pacemaker interference; Humacyte's $245M SPAC deal

Posted 27 August 2021 | By Kari Oakes 

Recon: FDA investigates iPhone-pacemaker interference; Humacyte's $245M SPAC deal

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
 
In Focus: US
  • FDA warns of pacemaker-iPhone interference (Healthcare IT News)
  • Opinion: Expanding the domestic public health supply chain is a matter of national security (STAT)
  • BD gets emergency FDA nod for smartphone-enabled COVID-19 antigen test (MedTech Dive)
  • Ivermectin Scripts, Poison Center Calls Boom During Delta Surge (MPT)
  • U.S. COVID-19 tests again in short supply as infections soar, schools reopen (Reuters)
  • States Pull Back on Covid Data Even Amid Delta Surge (KHN)
  • Regeneron, GSK see massive spike in Covid-19 mAb demand as US debates buying more (Endpoints)
  • Medicaid Vaccination Rates Founder as States Struggle to Immunize Their Poorest Residents (KHN)
In Focus: International
  • The Biden administration is being criticized for falling short on its pledge to provide vaccines to the world (NYT)
  • EU says Moderna COVID vaccine production can continue after contamination incident (Reuters)
  • BioNTech selects Rwanda, Senegal for potential malaria and tuberculosis mRNA vaccine manufacturing (Fierce)
  • Malaysia, Singapore Join Hands On Review Of Generic Drugs (Pink Sheet)
  • Mexico introduces new decree on health regulation (GaBi)
  • European Commission grants conditional approval of Minjuvi (Pharmaletter)
Coronavirus Pandemic
  • Why Is It Taking So Long to Get a Covid Vaccine for Kids? (NYT)
  • Vaccine inequality could cost the global economy trillions, report finds (CNBC)
  • Global policymakers urge more sharing of COVID-19 vaccine (Reuters)
  • Brii’s antibody combination could offer new COVID-19 option (Pharmaletter)
  • Covid — not vaccination — presents biggest blood clot risk, large study finds (CNBC)
  • Eurofarma to manufacturer Pfizer-BioNTech COVID-19 shot for Latin American market: Production set to exceed 100 million doses annually (BioPharma Reporter)
Pharma & Biotech
  • Humacyte $245 million richer after SPAC deal ahead of Nasdaq debut (Pharmaletter)
  • Vaxneuvance meets immunogenicity and safety endpoints in Phase III trial (EPR)
  • Agenus, with FDA approval in sight, showcases anti-PD-1 data (Fierce)
  • Xywav set to become Jazz’s next blockbuster in the narcolepsy market, says analyst (Pharmaletter)
  • BeyondSpring, flying high from phase 3 success, sells Chinese rights to cancer drug (Fierce)
  • Neurogastrx: $60M crossover round to advance de-risked GI assets (Biocentury)
  • COVID shot drives CanSinoBIO's first six-month profit since at least 2019 (Reuters)
  • Bolt, Innovent partner on non-traditional antibody conjugates (Biocentury)
  • Backed by Eli Lilly, a little-known and secretive Chinese biotech fills the tank as it heads to the clinic (Endpoints)
  • Foreign API Manufacturing Dominance Requires Long-Term Federal Intervention: Report (FDA News)
  • Sesen Bio Withdraws EU Application for Cancer Drug FDA Just Turned Down (FDA News)
  • Blood cancer therapy market: opportunities and challenges (Pharmaletter)
  • Real-World Data: ‘Don’t Take Your Foot Off the Gas’ (Pink Sheet)
  • Mayo, Verily strike two-year partnership to build decision support tools (MedCity News)
  • Pharmacist-driven biosimilar substitution saves money (GaBi)
Medtech
  • Foundation Medicine, Epic partner to integrate genomic insights into EHR (MedCity News)
  • Class 2 Device Recall Terumo Advanced Perfusion System 1 (FDA)
  • Demand for Qiagen's COVID-19 tests 'is here to stay' – CFO (Reuters)
  • New 3D Dental Tech Spin Out: Osteoid (MD+DI)
  • AppliedVR, Curebase to launch five studies of VR for chronic pain (MD+DI)
  • BOLD Laser Automation Debuts Laser Tools for Catheters and Stents (MD+DI)
Government, Regulatory & Legal
  • BMS to seek review of CAFC’s reversal of $1.2B judgment against Gilead (Biocentury)
  • The Cassava saga continues as testing partner denies preparing tainted Alzheimer's data (Endpoints)
  • Elizabeth Holmes Mental Health Docs May Be Unsealed Soon (Law360)
  • Bankruptcy judge: J&J can spin talc powder into different company, potentially slowing plaintiffs' payouts (Endpoints)
  • Stem Cell Clinic Says Ga. Lacks Authority To Bring $6.4M Suit (Law360)
  • Chancery Tosses Class Suit Over $3B Zimmer Biomet Cashout (Law360)
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe.
 
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
 

 

© 2022 Regulatory Affairs Professionals Society.